Role of peroxisome proliferator-activated receptor α and ϒ-2 in primary and secondary prophylaxis of atherosclerosis

Role of peroxisome proliferator-activated receptor α and ϒ-2 in primary and secondary prophylaxis of atherosclerosis

Literature review is devoted to the pathogenesis of atherosclerosis and pathogenetic mechanisms that determine the value of peroxisome proliferator-activated receptor (PPAR) in atherogenesis. PPAR α and ϒ-2 are nuclear receptors that regulate lipid and glucose metabolism, and immune inflammation in...

Full description

Saved in:

Bibliographic Details
Main Authors:	Z. I. Ionova, E. G. Sergeeva, O. A. Berkovich, S. N. Pchelina, E. I. Baranova
Format:	Article
Language:	Russian
Published:	Academician I.P. Pavlov First St. Petersburg State Medical University 2016-06-01
Series:	Учёные записки Санкт-Петербургского государственного медицинского университета им. Акад. И.П. Павлова
Subjects:	рецепторы активатора пролиферации пероксисом ppar тиазолидиндионы фибраты омега-3 пнжк статины алеглитазар
Online Access:	https://www.sci-notes.ru/jour/article/view/324
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

СОДЕРЖАНИЕ ОМЕГА-3 И ОМЕГА-6 ПОЛИНЕНАСЫЩЕННЫХ ЖИРНЫХ КИСЛОТ В ПЛАЗМЕ КРОВИ ВЗРОСЛОГО НАСЕЛЕНИЯ Г. САНКТ-ПЕТЕРБУРГА
by: Геннадий Георгиевич Родионов, et al.
Published: (2025-04-01)

Tiazolidindiony: pol'za ili risk?
by: Anastasia Sergeevna Severina
Published: (2007-12-01)

PLEIOTROPIC EFFECTS OF STATINS
by: Татьяна Евгеньевна Помыткина, et al.
Published: (2025-06-01)

Rol' statinov v korrektsii diabeticheskoy dislipidemii
by: L M Dobordzhginidze, et al.
Published: (2001-06-01)

Preimushchestva vklyucheniya v terapiyu bol'nykh s metabolicheskim sindromom i arterial'noy gipertenziey statinov: dopolnitel'nye vozmozhnosti organoprotektsii
by: M E Statsenko, et al.
Published: (2007-06-01)

PPARy - predstavitel' semeystva yadernykh steroidnykh retseptorov
by: Irina Vladimirovna Kononenko, et al.
Published: (2005-06-01)

News form the 35th annual meeting of the European Association on Study of Diabetes
by: Editorial team Diabetes Mellitus
Published: (2000-03-01)

«НЕПОТЕРЯННОЕ ВРЕМЯ» В ПРОФИЛАКТИКЕ РАЗВИТИЯ ОСЛОЖНЕНИЙ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙ: ОТДАЛЕННЫЕ РЕЗУЛЬТАТЫ ПРИМЕНЕНИЯ СТАТИНОВ С ЦЕЛЬЮ ПЕРВИЧНОЙ ПРОФИЛАКТИКИ
Published: (2016-12-01)

Antihyperglycemic and Hypolipidemic Activities of Flavonoids Isolated from Smilax Dominguensis Mediated by Peroxisome Proliferator-Activated Receptors
by: Erandi Ortiz-Barragán, et al.
Published: (2024-10-01)

PREDICTORS OF ADVERSE CLINICAL COURSE OF CORONARY HEART DISEASE: THE RESULTS FROM DYNAMICAL OBSERVATION
by: E. V. Shlyakhto, et al.
Published: (2018-08-01)

PERSONALIZED STATIN THERAPY IN IMPROVING THE TREATMENT OF CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS
by: U. R. Makhmudova, et al.
Published: (2015-06-01)

Novaya vekha v ispol'zovani statinov dlya profilaktiki i lecheniya serdechno-sosudistykh oslozhneniy (Po rezul'tatam Heart Protection Study ? HPS)
by: L Chugunova, et al.
Published: (2003-12-01)

Estrogen and progesterone receptors expression in uveal melanoma tumor cells
by: S. V. Saakyan, et al.
Published: (2018-10-01)

THE CONCERNS OF ROSUVASTATIN CLINICAL EFFICACY AND SAFETY
by: V. V. Kukharchuk, et al.
Published: (2013-06-01)

Potential involvement of peroxisome proliferator-activated receptors in the inhibition of mammary lipid synthesis during diet-induced milk fat depression
by: A. Haile, et al.
Published: (2025-02-01)

Natural killer cells: origin, phenotype, function
by: E. V. Tyshchuk, et al.
Published: (2021-12-01)

АССОЦИАЦИЯ ПЛАЗМЕННЫХ УРОВНЕЙ ЭКТОПИЧЕСКОГО ВКУСОВОГО РЕЦЕПТОРА TAS2R5 С КЛИНИКО-ФУНКЦИОНАЛЬНЫМИ ХАРАКТЕРИСТИКАМИ БРОНХИАЛЬНОЙ АСТМЫ
by: Михаил Александрович Нёма, et al.
Published: (2025-08-01)

Primenenie mevakora i alisata pri metabolicheskom sindrome
by: E N Mel'chinskaya, et al.
Published: (2000-06-01)

Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
by: Ana Paula Madariaga Traconis, et al.
Published: (2024-12-01)

Acetoacetate Ameliorates Hepatic Fibrosis by Targeting Peroxisome Proliferator-Activated Receptor Gamma to Restore Lipid Droplets in Activated Hepatic Stellate Cells
by: Ya Zhou, et al.
Published: (2025-02-01)

Pemafibrate modulates peroxisome proliferator-activated receptor alpha and prevents alcohol-associated liver disease in rats
by: Takashi Saito, et al.
Published: (2025-04-01)

Retinoid X receptor γ interacts with peroxisome proliferator-activated receptor-γ to promote browning during adipose tissue differentiation
by: Defei Chen, et al.
Published: (2025-12-01)

The Versatile Role of Peroxisome Proliferator-Activated Receptors in Immune-Mediated Intestinal Diseases
by: Edit Posta, et al.
Published: (2024-10-01)

Pharmacological inhibition of Peroxisome Proliferation-Activated Receptor Delta (PPARδ) imparts selective leukemia cell death
by: Yingying Yang, et al.
Published: (2025-07-01)

Современные аспекты организации молекул главного комплекса гистосовместимости и особенности развития иммунного ответа
by: Александр Витальевич Москалев, et al.
Published: (2024-11-01)

The clinical role of blood coagulation and platelet receptors gene allelic variants in development of Wilson’s disease
by: T. P. Rozina, et al.
Published: (2018-08-01)

IRON DEFICIENCY ANEMIA AND ANEMIA OF CHRONIC DISEASES: SOME ASPECTS OF THE PATHOGENESIS AND PROSPECTS OF DIFFERENTIAL DIAGNOSIS
by: Сатеник Аршавиловна Клочкова-Абельянц, et al.
Published: (2019-09-01)

Evaluation of C-X-C chemokine receptor type 4 (CXCR4) and Peroxisome proliferator-activated receptor gamma (PPAR-γ) expression in colorectal carcinoma: Relation to the available clinicopathological parameters
by: Asmaa E. Bedeer, et al.
Published: (2023-07-01)

Аlterationdegree of NMDA and AMPA receptors of glutamate in the pathogenesis of the disease and technological peculiarities of surgical treatment of the hemispheric glioma-swith the epileptic syndrome
by: V. N. Ochkolyas, et al.
Published: (2014-06-01)

THE INFLUENCE OF HYPOLIPIDEMIC THERAPY ON THE LEVEL OF MODIFIED LOW DENSITY LIPOPROTEIDES
by: V. Z. Lankin, et al.
Published: (2018-09-01)

THE ROLE OF THE PROPROTEIN CONVERTASE SUBTILISIN / KEXIN TYPE 9 (PCSK9) IN THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS
by: Алексей Михайлович Чаулин, et al.
Published: (2019-12-01)

Прогностичне значення маркерів ендотеліальної дисфункції в діагностиці ступеня атеросклеротичного ураження коронарних судин у хворих із гострим інфарктом міокарда з коронарним стентуванням
by: D. V. Minukhina, et al.
Published: (2018-09-01)

PROTEINS-REGULATORS OF IRON METABOLISM IN THE DIFFERENTIAL DIAGNOSIS OF IRON-DEFICIENCY ANEMIA
by: Галина Северьевна Суржикова, et al.
Published: (2022-08-01)

Sostoyanie tsitoplazmaticheskikh membran pri eksperimental'nom sakharnom diabete
by: N P Mikaelyan, et al.
Published: (1999-09-01)

Peroxisome Proliferator‐Activated Receptor (PPAR) Agonists for Patients With Primary Biliary Cholangitis With Inadequate Response to Ursodeoxycholic Acid (UDCA): A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
by: Maadeha H. Zaidi, et al.
Published: (2025-06-01)

Effect of Pemafibrate, a Selective Peroxisome Proliferator-activated Receptor ? Modulator (SPPARM?), on the Lipid Profile, Liver Function, and Liver Fibrosis among Patients with Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
by: Mona Hassan, et al.
Published: (2025-06-01)

Exacerbation of atherosclerosis, hyperlipidemia and inflammation by MK886, an inhibitor of leukotriene biosynthesis, in obese and diabetic mice
by: Katherine Keever, et al.
Published: (2024-01-01)

Peroxisome proliferator‐activated receptor gamma (PPARγ) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target
by: Oren Pleniceanu, et al.
Published: (2017-03-01)

A “υ-Operation Free” Approach to Prüfer υ-Multiplication Domains
by: Marco Fontana, et al.
Published: (2009-01-01)

LAICIDAD Υ ANTICLERICALISMO
by: SEBASTIÁN RUDAS
Published: (2019-01-01)